How IL-17 Inhibitors Measure Up Against Other Biologics

How do IL-17 inhibitors compare with other biologic therapies for psoriasis and psoriatic arthritis? Following his Fall Clinical presentation with Mark Lebwohl, MD, Brad Glick, DO, revisits the head-to-head evidence, highlighting speed of response as an important consideration in evaluating treatment options. His recap brings comparative efficacy into focus as clinicians weigh the expanding range of biologic therapies available to patients.